Ajinomoto Co., Ltd.

Toshihiro Hatanaka

Nobuo Kondo

Hiroyuki Matsueda

Koji Ohsumi

Katsumi Maezono

Yoko Kageyama

Yoko Masuzawa

Ryusuke Hirama

Seiji Niwa

Takao Ikenoue

Akiyo Yamazaki

Takashi Umemura

Akiko Onuki

Takashi Yamamoto

Hideyuki Tanaka

Yukio Iino

Nozomu Ishida

Yayoi Kawato

Fumio Ohta

Yuzuru Eto

Masayuki Sugiki

Sayaka Asari

Naohiro Miyamura

Masaru Takayanagi

Hiroaki Nagasaki

Tetsuo Yano

Reiko Yasuda

Yukio Nihei

Wataru Miyanaga

Toru Okamatsu

Yukie Seki

Tsuyoshi Kobayashi

Nobuyasu Suzuki

Takashi Tsuji

Toshihiko Yoshimura

Eiji Nakanishi

Naoyuki Fukuchi

Kazuo Ohishi

Koichi Fujita

Kenji Takehana

Atsushi Konishi

Osamu Ikehara

Ariko Kodaira

Ryusuke Nakagawa

Hidehiro Ichinose

Noriko Yasa

By searching various kinds of compounds having CaSR agonistic activity, the present invention provides CaSR agonistic agents, pharmaceutical compositions, preventive or therapeutic agents for diarrhea and kokumi-imparting agents each of which comprise the compound. More specifically, the present invention provides CaSR agonistic agents, pharmaceutical compositions, preventive or therapeutic agents for diarrhea and kokumi-imparting agents each of which comprise a glutamic acid derivative having CaSR agonistic activity or pharmaceutically acceptable salts thereof.

CaSR agonists

The present invention provides a fused polycyclic compound of the following formula, analogues thereof and pharmaceutically acceptable salts thereof; and agents for increasing the sugar-transporting capacity, hypoglycemic agents and pharmaceutical compositions containing the above compounds. This fused polycyclic compound has high medicinal properties and few side-effects, and a therapeutic effect on diabetes. wherein R represents an alkoxy group, R' represents an oxazolylpropionyl group or a thiazolylpropionyl group, and R&#x2033; represent a hydrogen atom.

Fused polycyclic compounds having a heterocyclic ring(s) and pharmaceutical use thereof

The invention provides a prophylactic and therapeutic agent of diabetes mellitus, including a combination of an inhibitor of renal glucose reabsorption and a hypoglycemic agent. In accordance with the invention, hyperglycemia after meals, between meals and during fasting can be ameliorated. More specifically, in accordance with the invention, a therapeutic effect of diabetes mellitus as never been obtained by the hypoglycemic agents of the related art can be achieved.

Prophylactic and therapeutic agent of diabetes mellitus

The present invention provides an acylamide compound of the following formula (1), prodrugs thereof, or pharmaceutically acceptable salts thereof; and an adiponectin inducer or secretagogue, therapeutic agent of metabolic syndromes, therapeutic agent of hypoadiponectinemia, therapeutic agent of hyperlipemia, preventive/therapeutic agent of diabetes, improving agent of impaired glucose tolerance, improving agent of insulin resistance, enhancing agent of insulin sensitivity, therapeutic agent of hypertension, preventive/therapeutic agent of vascular disorders, an anti-inflammatory agent, therapeutic agent of hepatic inflammation, therapeutic agent of fatty liver, therapeutic agent of hepatic fibrosis, therapeutic agent of liver cirrhosis, preventive/therapeutic agent of non-alcoholic/nonviral steatohepatitis (NASH) or non-alcoholic/nonviral fatty liver disease (NAFLD), or therapeutic agent of obesity, each of which has the above compounds as an active ingredient. 

Acylamide compounds having secretagogue or inducer activity of adiponectin

The present invention provides pyrazole-O-glycoside derivatives represented by the following formulae, used as a diabetic medicine. 

Pyrazole derivatives and diabetic medicine containing them

An agent for increasing the sugar-transporting capacity and an agent for preventing and/or treating diabetes, diabetic peripheral neuropathy, diabetic nephropathy, diabetic retinopathy, diabetic macroangiopathy, impaired glucose tolerance or adiposis, which contains a lactam compound or a pharmaceutically acceptable salt thereof as the active ingredient.

Lactam compounds and pharmaceutical use thereof

The present invention provides novel benzene compounds presented by the following formulas, and analogs thereof, that exert an ACC activity-inhibiting effect that is effective in the treatment of obesity, hyperlipemia, fatty liver, hyperglycemia, impaired glucose tolerance, diabetes, diabetic complications (diabetic peripheral neuropathy, diabetic nephropathy, diabetic retinopathy, and diabetic macroangiopathy, hypertension, arteriosclerosis), hypertension, and arteriosclerosis. 

Benzene compounds

The present invention provides pyrazole-O-glycoside derivatives represented by the following formulae, used as a diabetic medicine 

The present invention provides pyrazole-O-glycoside derivatives represented by the following formulae, used as a diabetic medicine.

The present invention relates to pyrazole derivatives represented by the following formulas and analogues thereof, which can be used for a therapeutic agent for diabetes.

N-substituted pyrazole-O-glycoside derivatives and therapeutic agent for diabetes containing the same

Growing community of inventors

Kawasaki, Japan

Toshihiro Hatanaka